Drug Overview
Abraxane (nab-paclitaxel; Celgene/Taiho) is an albumin-bound formulation of paclitaxel, an anti microtubule taxane that interferes with the growth of tumors by inhibiting mitosis during metaphase. Standard forms of paclitaxel require solvents such as Cremophor (polyoxyethylated castor oil) to allow for intravenous administration. Such lipid-based solvents can lead to potentially severe hypersensitivity reactions, and may require the premedication of patients with steroids prior to each treatment. Abraxane’s novel albumin-bound formulation makes it readily soluble in saline, and eliminates the need for toxic solvents. Preclinical studies of Abraxane have also demonstrated increased paclitaxel transport across endothelial cells and greater antitumor activity compared to standard paclitaxel.
Abraxane (nab-paclitaxel; Celgene/Taiho) is an albumin-bound formulation of paclitaxel, an anti microtubule taxane that interferes with the growth of tumors by inhibiting mitosis during metaphase. Standard forms of paclitaxel require solvents such as Cremophor (polyoxyethylated castor oil) to allow for intravenous administration. Such lipid-based solvents can lead to potentially severe hypersensitivity reactions, and may require the premedication of patients with steroids prior to each treatment. Abraxane’s novel albumin-bound formulation makes it readily soluble in saline, and eliminates the need for toxic solvents. Preclinical studies of Abraxane have also demonstrated increased paclitaxel transport across endothelial cells and greater antitumor activity compared to standard paclitaxel.
Table of Contents
OVERVIEWDrug Overview
Product Profiles
Abraxane : Non-small cell lung cancer (NSCLC)
Abraxane : Gastric cancer
Abraxane : Breast cancer: triple-negative
LIST OF FIGURES
Figure 1: Abraxane for non-small cell lung cancer – SWOT analysis
Figure 2: The authors drug assessment summary for Abraxane in non-small cell lung cancer
Figure 3: The authors drug assessment summary for Abraxane in non-small cell lung cancer
Figure 4: Abraxane sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 5: Abraxane for gastric cancer – SWOT analysis
Figure 6: The authors drug assessment summary of Abraxane for gastric cancer
Figure 7: The authors drug assessment summary of Abraxane for gastric cancer
Figure 8: Abraxane sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017–26
Figure 9: Abraxane for triple-negative breast cancer – SWOT analysis
Figure 10: The authors drug assessment summary of Abraxane for triple-negative breast cancer
Figure 11: The authors drug assessment summary of Abraxane for triple-negative breast cancer
LIST OF TABLES
Table 1: Abraxane drug profile
Table 2: Abraxane pivotal trial data in non-small cell cancer
Table 3: Ongoing late-phase trials
Table 4: Abraxane late-phase trial data in non-small cell lung cancer
Table 5: Abraxane sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 6: Abraxane patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
Table 7: Abraxane drug profile
Table 8: Abraxane pivotal trial data in gastric cancer
Table 9: Abraxane sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 10: Abraxane patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017–26
Table 11: Abraxane drug profile
Table 12: Abraxane pivotal trial data in triple-negative breast cancer
Table 13: Abraxane late-phase trial data in triple-negative breast cancer
Table 14: Abraxane ongoing late-phase clinical trials in triple-negative breast cancer
